Non-interventional, retrospective study of advanced SCLC patients in 4 European countries (France, Germany, Italy, and United Kingdom [UK]) with the aim to produce evidence across different SCLC treatment lines to characterize the clinical and economic burden of the disease in Europe.

Inclusion Criteria:

Cohort 1 and 2:

• Patients 18 years of age or older at SCLC diagnosis
• Confirmed diagnosis of SCLC within the patient identification period (between October 2013 and October 2015)
• Initiated on first-line treatment (radiotherapy and/or chemotherapy) for their SCLC
• Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first)
• Signed informed consent (where required as per local requirements)

Cohort 3:

• Patients 18 years of age or older at SCLC diagnosis
• Confirmed diagnosis of SCLC not earlier than October 2013
• Initiated on second-line treatment due to relapse after first-line therapy not later than August 2016
• Full oncology medical history for the mandatory variables of the study available in the participating center from day of diagnosis until the end of follow-up or death (whichever occurs first)
• Signed informed consent (where required as per local requirements)

Exclusion Criteria:

• Participants with previous malignancies (except non-melanoma skin cancers, and in situ cancers such as the following: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to first treatment and no additional therapy is required or anticipated to be required during the study period.

Other Inclusion/Exclusion criteria may apply

Advanced SCLC patients in 4 European countries (France, Germany, Italy, and United Kingdom [UK]).